Structural dynamics at the active site of the cancer-associated flavoenzyme NQO1 probed by chemical modification with

Alice Grieco1, Miguel A Ruiz-Fresneda2, Atanasio Gómez-Mulas3

  • 1Department of Crystallography & Structural Biology, Institute of Physical Chemistry Blas Cabrera, Spanish National Research Council (CSIC), Madrid, Spain.

FEBS Letters
|September 19, 2023
PubMed

Insights

Human NAD(P)H:quinone oxidoreductase 1 (NQO1) retains activity even when covalently bound to PMSF. This suggests targeting Tyr128 may not be an effective drug strategy for inhibiting NQO1.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Enzymology

Background:

  • Human NAD(P)H:quinone oxidoreductase 1 (NQO1) is a flavoprotein implicated in various diseases.
  • Conformational heterogeneity in the NQO1 catalytic site is a known characteristic.
  • Understanding NQO1's structural dynamics is crucial for therapeutic development.

Purpose of the Study:

  • To determine the X-ray structure of NQO1 in complex with phenylmethylsulfonyl fluoride (PMSF).
  • To investigate the impact of PMSF covalent binding on NQO1 activity and catalytic site flexibility.
  • To evaluate the potential of targeting Tyr128 for NQO1 inhibition.

Main Methods:

  • X-ray crystallography to obtain the NQO1-PMSF complex structure at 1.6 Å resolution.
  • Enzyme activity assays to measure NQO1 function in the presence of PMSF.

Main Results:

  • The crystal structure revealed PMSF covalently bound to the Tyr128 residue within the NQO1 catalytic site.
  • Activity assays demonstrated that PMSF binding did not abolish NQO1 activity.
  • The results suggest PMSF does not significantly restrict the flexibility of Tyr128, allowing substrate binding.

Conclusions:

  • Covalent modification of Tyr128 with PMSF does not inhibit NQO1 activity.
  • The flexibility of Tyr128 may be maintained despite PMSF binding, enabling substrate interaction.
  • Targeting Tyr128 with small, covalently binding molecules may not be a viable strategy for developing NQO1 inhibitors.